Inhibikase Therapeutics Inc IKT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/03/24 EDT
1.39quote price arrow up+0.05 (+3.73%)
Volume
46,539
52 week range
0.79 - 4.35
Loading...
  • Open1.38
  • Day High1.51
  • Day Low1.33
  • Prev Close1.34
  • 52 Week High4.35
  • 52 Week High Date06/02/23
  • 52 Week Low0.79
  • 52 Week Low Date10/10/23

Key Stats

  • Market Cap9.003M
  • Shares Out6.48M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.32
  • YTD % Change9.45

KEY STATS

  • Open1.38
  • Day High1.51
  • Day Low1.33
  • Prev Close1.34
  • 52 Week High4.35
  • 52 Week High Date06/02/23
  • 52 Week Low0.79
  • 52 Week Low Date10/10/23
  • Market Cap9.003M
  • Shares Out6.48M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.32
  • YTD % Change9.45

RATIOS/PROFITABILITY

  • EPS (TTM)-3.62
  • P/E (TTM)-0.38
  • Fwd P/E (NTM)-0.73
  • EBITDA (TTM)-19.912M
  • ROE (TTM)-118.88%
  • Revenue (TTM)260,500.014
  • Gross Margin (TTM)-
  • Net Margin (TTM)-7,304.76%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/13/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Inhibikase Therapeutics Inc

 

Profile

MORE
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson...
Milton Werner Ph.D.
President, Chief Executive Officer, Director
Garth Lees-Rolfe
Chief Financial Officer
Address
3350 Riverwood Parkway Se, Suite 1900
Atlanta, GA
30339
United States